Patrick Hwu
A5033798832- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- Cutaneous Melanoma Detection and Management
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Biomedical Ethics and Regulation
- Virus-based gene therapy research
- Monoclonal and Polyclonal Antibodies Research
- Click Chemistry and Applications
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Brain Metastases and Treatment
- Synthesis of Tetrazole Derivatives
- Computational Drug Discovery Methods
- vaccines and immunoinformatics approaches
- PI3K/AKT/mTOR signaling in cancer
- Protein Degradation and Inhibitors
- HER2/EGFR in Cancer Research
- Synthesis and biological activity
- Ferroptosis and cancer prognosis
- Nanoplatforms for cancer theranostics
- Epigenetics and DNA Methylation
Moffitt Cancer Center
2011-2025
The University of Texas MD Anderson Cancer Center
2015-2024
Melanoma Institute Australia
2008-2023
The University of Texas Health Science Center at Houston
2013-2022
Dana-Farber Cancer Institute
2013-2019
Massachusetts General Hospital
2013-2019
Broad Institute
2019
Harvard University
2019
The Wistar Institute
2019
Deutschen Konsortium für Translationale Krebsforschung
2019
Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, neutralizing antibody against factor, patients with metastatic renal-cell carcinoma.A randomized, double-blind, phase 2 was comparing placebo bevacizumab at doses 3 and 10 mg per kilogram body weight, given every two weeks; time progression disease response rate were primary end points. Crossover from...
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical immunoregulatory molecule (expressed on activated cells and subset of regulatory cells) capable down-regulating cell activation. Blockade CTLA-4 has been shown in animal models to improve the effectiveness cancer immunotherapy. We thus treated 14 patients with metastatic melanoma by using serial i.v. administration fully human anti-CTLA-4 antibody (MDX-010) conjunction s.c. vaccination two modified HLA-A * 0201-restricted...
Abstract Purpose: A phase I study was conducted to assess the safety of adoptive immunotherapy using gene-modified autologous T cells for treatment metastatic ovarian cancer. Experimental Design: with reactivity against cancer–associated antigen α-folate receptor (FR) were generated by genetic modification a chimeric gene incorporating an anti-FR single-chain antibody linked signaling domain Fc γ chain. Patients assigned one two cohorts in study. Eight patients cohort 1 received dose...
To evaluate the effects of BRAF inhibition on tumor microenvironment in patients with metastatic melanoma.Thirty-five biopsies were collected from 16 melanoma pretreatment (day 0) and at 10 to 14 days after initiation treatment either inhibitor alone (vemurafenib) or + MEK (dabrafenib trametinib) also taken time progression. Biopsies analyzed for antigens, T-cell markers, immunomodulatory cytokines.Treatment was associated an increased expression antigens increase CD8+ infiltrate. This a...
Stimulating an immune response against cancer with the use of vaccines remains a challenge. We hypothesized that combining melanoma vaccine interleukin-2, activating agent, could improve outcomes. In previous phase 2 study, patients metastatic receiving high-dose interleukin-2 plus gp100:209-217(210M) peptide had higher rate than is expected among who are treated alone.We conducted randomized, 3 trial involving 185 at 21 centers. Eligibility criteria included stage IV or locally advanced III...
Purpose: This three-arm randomized study compares response rates and overall survival of patients with metastatic renal cell cancer (RCC) receiving high-dose or one two low-dose interleukin-2 (IL-2) regimens. Patients Methods: measurable RCC a good performance status were to receive either 720,000 U/kg (high-dose [HD]) 72,000 (low-dose [LD]), both given by intravenous (IV) bolus every 8 hours. After randomly assigning 117 patients, third arm daily subcutaneous IL-2 was added, an additional...
Abstract IL-21 is a type I cytokine whose receptor expressed on T, B, and NK cells. Within the B cell lineage, regulates IgG1 production cooperates with IL-4 for of multiple Ab classes in vivo. Using IL-21-transgenic mice hydrodynamics-based gene delivery plasmid DNA into wild-type as well vitro studies, we demonstrate that although induces death resting cells, it promotes differentiation cells postswitch plasma Thus, differentially influences fate depending signaling context, explaining how...
Abstract BACKGROUND: There is a need for improved prognostic markers in melanoma. In this study, the authors tested significance and clinicopathologic correlations of v‐raf murine sarcoma viral oncogene homolog B1 ( BRAF ) neuroblastoma RAS (v‐ ras NRAS mutations patients with metastatic METHODS: Clinical pathologic data were collected retrospectively on melanoma who clinically (exon 15) (exons 1 2) at The University Texas M. D. Anderson Cancer Center. Analyses performed to identify...
PURPOSE: A strain of Salmonella typhimurium (VNP20009), attenuated by chromosomal deletion the purI and msbB genes, was found to target tumor inhibit growth in mice. These findings led present phase I study intravenous infusion VNP20009 patients with metastatic cancer. PATIENTS AND METHODS: In cohorts consisting three six patients, 24 melanoma one patient renal cell carcinoma received 30-minute bolus infusions containing 10 6 9 cfu/m 2 VNP20009. Patients were evaluated for dose-related...
Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer, but effect of diet and supplements on this interaction is not well studied. We assessed fecal microbiota profiles, dietary habits, commercially available probiotic supplement use melanoma patients performed parallel preclinical studies. Higher fiber was associated with significantly improved progression-free survival 128 ICB, most pronounced benefit observed sufficient intake no use. Findings were...
BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose this study was to determine the response rate (RR) for selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma.This an open-label, two-stage, phase II two cohorts. Patients previously treated a (cohort A) or chemotherapy and/or immunotherapy (BRAF-inhibitor naive; cohort B) were enrolled. received 2 mg orally once...
The tumor-associated-Ag MART-1 is expressed by most human melanomas. genes encoding an alphabeta TCR from a MART-1-specific, HLA-A2-restricted, T cell clone have been efficiently transferred and in PBL. These retrovirally transduced PBL cultures were peptide reactive, recognized HLA-A2+ melanoma lines. Limiting dilution clones generated three bulk to investigate the function of individual within cultures. Twenty-nine 29 CD8+ specifically secreted IFN-gamma response T2 cells pulsed with...
Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) is a promising treatment for metastatic melanoma unresponsive to conventional therapies. We report here on the results of an ongoing phase II clinical trial testing efficacy ACT TIL in patients with and association specific patient characteristics phenotypic attributes infused response.
Abstract There is a critical need to improve our understanding of the pathogenesis melanoma brain metastases (MBM). Thus, we performed RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial metastases; tumors with sufficient tissue also underwent whole-exome sequencing, T-cell receptor IHC. demonstrated heterogeneity immune infiltrates that correlated prior radiation post-craniotomy survival. Comparison identified significant immunosuppression enrichment oxidative...
Monoclonal antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4) used for treatment of metastatic melanoma produce inflammatory immune-related adverse events. The purpose the current study was to retrospectively identify and characterize radiologic manifestations events evaluate possible association between these clinical responses anti-CTLA-4 therapy.We reviewed images medical records 119 patients with treated at our institution assessed presence therapy. were categorized as...